Core Set of Patient-Reported Outcome Measures for Measuring Quality of Life in Clinical Obesity Care

Phillip J. Dijkhorst, Valerie M. Monpellier, Caroline B. Terwee, Ronald S.L. Liem, Bart A. van Wagensveld, Ignace M.C. Janssen, Johan Ottosson, Bruno Halpern, Stuart W. Flint, Elisabeth F.C. van Rossum, Alend Saadi, Lisa West-Smith, Mary O’Kane, Jason C.G. Halford, Karen D. Coulman, Salman Al-Sabah, John B. Dixon, Wendy A. Brown, Ximena Ramos Salas, Sally AbbottAlyssa J. Budin, Jennifer F. Holland, Lotte Poulsen, Richard Welbourn, Natasja Wijling, Laura Divine, Nadya Isack, Susie Birney, J. M.Bernadette Keenan, Theodore K. Kyle, Melanie Bahlke, Andrew Healing, Ian Patton, Claire E.E. de Vries

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
91 Downloads (Pure)

Abstract

Purpose: The focus of measuring success in obesity treatment is shifting from weight loss to patients’ health and quality of life. The objective of this study was to select a core set of patient-reported outcomes and patient-reported outcome measures to be used in clinical obesity care. Materials and Methods: The Standardizing Quality of Life in Obesity Treatment III, face-to-face hybrid consensus meeting, including people living with obesity as well as healthcare providers, was held in Maastricht, the Netherlands, in 2022. It was preceded by two prior multinational consensus meetings and a systematic review. Results: The meeting was attended by 27 participants, representing twelve countries from five continents. The participants included healthcare providers, such as surgeons, endocrinologists, dietitians, psychologists, researchers, and people living with obesity, most of whom were involved in patient representative networks. Three patient-reported outcome measures (patient-reported outcomes) were selected: the Impact of Weight on Quality of Life-Lite (self-esteem) measure, the BODY-Q (physical function, physical symptoms, psychological function, social function, eating behavior, and body image), and the Quality of Life for Obesity Surgery questionnaire (excess skin). No patient-reported outcome measure was selected for stigma. Conclusion: A core set of patient-reported outcomes and patient-reported outcome measures for measuring quality of life in clinical obesity care is established incorporating patients’ and experts’ opinions. This set should be used as a minimum for measuring quality of life in routine clinical practice. It is essential that individual patient-reported outcome measure scores are shared with people living with obesity in order to enhance patient engagement and shared decision-making. Graphical Abstract: (Figure presented.)

Original languageEnglish
Pages (from-to)2980-2990
Number of pages11
JournalObesity Surgery
Volume34
Issue number8
Early online date15 Jul 2024
DOIs
Publication statusPublished - 1 Aug 2024

Bibliographical note

© The Author(s) 2024.
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/

Funder

Claire E. E. de Vries and Valerie M. Monpellier founded the S.Q.O.T. initiative. The initiative was cofounded by Bart A. van Wagensveld, Ignace M. C. Janssen, and Ronald S. L. Liem. Phillip J Dijkhorst joined the board of the S.Q.O.T. initiative in 2021. Claire E. E. de Vries, Ronald S. L. Liem, and Lotte Poulsen were involved in developing the eating scales in the BODY-Q. Claire E.E. de Vries and Ronald S. L. Liem are members of the organizing committee and were not permitted to participate in, nor influence, discussions during the S.Q.O.T. consensus meetings or the voting rounds. Lotte Poulsen was not permitted to participate in the voting rounds if the BODY-Q was available for a specific patient-reported outcome domain. None of the aforementioned persons received financial compensation for developing the BODY-Q or for any other BODY-Q-related activity. Ignace M. C. Janssen was a consultant at Johnson & Johnson and the Dutch Obesity Clinic. Johan Ottosson previously sat on the advisory board of Novo Nordisk. The University of Leeds received payments for Professor Halford\u2019s work on ACTION-Teens. Over the last 3 years, Stuart W. Flint reported research grants from the National Institute for Health Research, the Office of Health Improvement & Disparities, Public Health England, Doncaster Council, West Yorkshire Combined Authority, Johnson & Johnson, Novo Nordisk, and the University of Leeds. He reported receiving personal fees from the Royal College of General Practitioners and institutional fees from Public Health England, and he received funding to attend meetings at the parliament of the UK, Novo Nordisk, Johnson & Johnson, and Safefood. Stuart W. Flint also reported unpaid roles with Obesity UK. Bruno Halpern sat on the advisory boards of Novo Nordisk, Lilly, and Astra Zeneca. Additionally, he received lecture fees from Novo Nordisk, Astra Zeneca, Merck, and Abbott Nutrition. Furthermore, BH conducted clinical trials in collaboration with Novo Nordisk, Lilly, and Boehringer Ingelheim. John B. Dixon was a consultant at and sat on the advisory boards of Nestle Health Science and Reshape Lifesciences. He also sat on the advisory boards and also received speaker fees from Novo Nordisk and Lilly.

Funding

Claire E. E. de Vries and Valerie M. Monpellier founded the S.Q.O.T. initiative. The initiative was cofounded by Bart A. van Wagensveld, Ignace M. C. Janssen, and Ronald S. L. Liem. Phillip J Dijkhorst joined the board of the S.Q.O.T. initiative in 2021. Claire E. E. de Vries, Ronald S. L. Liem, and Lotte Poulsen were involved in developing the eating scales in the BODY-Q. Claire E.E. de Vries and Ronald S. L. Liem are members of the organizing committee and were not permitted to participate in, nor influence, discussions during the S.Q.O.T. consensus meetings or the voting rounds. Lotte Poulsen was not permitted to participate in the voting rounds if the BODY-Q was available for a specific patient-reported outcome domain. None of the aforementioned persons received financial compensation for developing the BODY-Q or for any other BODY-Q-related activity. Ignace M. C. Janssen was a consultant at Johnson & Johnson and the Dutch Obesity Clinic. Johan Ottosson previously sat on the advisory board of Novo Nordisk. The University of Leeds received payments for Professor Halford\u2019s work on ACTION-Teens. Over the last 3 years, Stuart W. Flint reported research grants from the National Institute for Health Research, the Office of Health Improvement & Disparities, Public Health England, Doncaster Council, West Yorkshire Combined Authority, Johnson & Johnson, Novo Nordisk, and the University of Leeds. He reported receiving personal fees from the Royal College of General Practitioners and institutional fees from Public Health England, and he received funding to attend meetings at the parliament of the UK, Novo Nordisk, Johnson & Johnson, and Safefood. Stuart W. Flint also reported unpaid roles with Obesity UK. Bruno Halpern sat on the advisory boards of Novo Nordisk, Lilly, and Astra Zeneca. Additionally, he received lecture fees from Novo Nordisk, Astra Zeneca, Merck, and Abbott Nutrition. Furthermore, BH conducted clinical trials in collaboration with Novo Nordisk, Lilly, and Boehringer Ingelheim. John B. Dixon was a consultant at and sat on the advisory boards of Nestle Health Science and Reshape Lifesciences. He also sat on the advisory boards and also received speaker fees from Novo Nordisk and Lilly.

FundersFunder number
Johnson & Johnson
Office of Health Improvement & Disparities
Novo Nordisk
Doncaster Council
West Yorkshire Combined Authority
National Institute for Health and Care Research
University of Leeds
Public Health England

    Keywords

    • Bariatric surgery
    • Clinical practice
    • Obesity treatment
    • Outcome reporting
    • Patient-reported outcome measures
    • Patient-reported outcomes
    • Quality of life

    ASJC Scopus subject areas

    • Surgery
    • Endocrinology, Diabetes and Metabolism
    • Nutrition and Dietetics

    Fingerprint

    Dive into the research topics of 'Core Set of Patient-Reported Outcome Measures for Measuring Quality of Life in Clinical Obesity Care'. Together they form a unique fingerprint.

    Cite this